USPTO Examiner LALONDE ALEXANDRA ELIZABETH - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19064155MEDICAMENT DELIVERY DEVICEFebruary 2025October 2025Allow711NoNo
18829229PRESSURE RIGIDIZATION APPARATUSES AND METHODSSeptember 2024July 2025Allow1011YesNo
18739243INJECTION DEVICES AND SYSTEMS AND METHODS FOR USING THEMJune 2024February 2026Allow2021NoNo
18716499COUPLING SYSTEM FOR FLUID TRANSFERJune 2024August 2025Abandon1420NoNo
18645975Genderless Aseptic ConnectorApril 2024December 2024Allow810NoNo
18638166MEDICAMENT DELIVERY DEVICEApril 2024February 2025Allow1010YesNo
18603079SYRINGE STABILIZERMarch 2024February 2026Allow2310NoNo
18590711ATTACHMENT MECHANISM, MODULE AND ASSEMBLY HEREWITHFebruary 2024March 2025Allow1321NoNo
18406013SYSTEM AND METHOD FOR DRAWING A SOLUTIONJanuary 2024December 2025Allow2330NoNo
18394502FLUIDICS MANAGEMENT SYSTEMDecember 2023October 2024Allow1020YesNo
18502803DEVICES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISCOGENIC BACK PAINNovember 2023September 2024Allow1110YesNo
18497142SYSTEM AND METHODS FOR INTRACRANIAL VESSEL ACCESSOctober 2023March 2026Allow2840YesNo
18374288DRUG DELIVERY DEVICE HAVING A NEEDLE GUARD MECHANISM WITH A TURNABLE THRESHOLD OF RESISTANCE TO NEEDLE GUARD MOVEMENTSeptember 2023December 2025Allow2750NoNo
18552893ASPIRATION AND INJECTION DEVICESSeptember 2023July 2024Allow1011YesNo
18238348INFUSION DEVICE AND METHODAugust 2023December 2024Allow1511NoNo
18229963ENDOVASCULAR REMOTELY STEERABLE GUIDEWIRE CATHETERAugust 2023September 2024Allow1310NoNo
18361716INTRAOCULAR IMPLANT DELIVERY APPARATUS AND METHODS OF USE THEREOFJuly 2023July 2025Abandon2311NoNo
18358147ACTIVATION SYSTEM AND METHOD FOR ON-BODY MEDICAL DEVICESJuly 2023December 2024Allow1711YesNo
18358229FLOW INDICATOR FOR AN INFUSION PUMPJuly 2023August 2024Allow1310NoNo
18141680APPARATUS AND METHODS FOR DISPENSING ORAL TRANSMUCOSAL DOSAGE FORMSMay 2023March 2025Abandon2330NoNo
18139698Integrated Pump Control For Dynamic Control Of Plasma FieldApril 2023March 2024Allow1110YesNo
18043873CATHETERS ADAPTED FOR AGENT DELIVERYMarch 2023February 2025Allow2421NoNo
18041104Features for Angiography SyringeFebruary 2023March 2024Allow1421NoNo
18107422HIATAL HERNIA TREATMENTFebruary 2023May 2024Allow1511YesNo
18095601DELIVERY DEVICEJanuary 2023August 2025Allow3150NoNo
18092838METHOD AND DEVICE FOR SECLUDING A BODY VESSELJanuary 2023August 2025Abandon3130NoNo
18073126INTRAVENOUS PRIMING CAPDecember 2022February 2024Allow1410YesNo
17981998Adaptor for Connecting a Drug Delivery Device to a ConnectorNovember 2022August 2025Allow3340YesNo
18048783DRUG DEPOT DELIVERY SYSTEM AND METHODOctober 2022February 2024Allow1620YesNo
17931162DRUG DELIVERY DEVICE AND METHODSeptember 2022November 2023Allow1420YesNo
17901360INFUSING DRUG SOLUTION DIRECTLY INTO BRAIN FLUIDSeptember 2022April 2025Allow3140YesYes
17886199HIGH FLEXIBILITY, KINK RESISTANT CATHETER SHAFTAugust 2022February 2026Allow4350YesNo
17860574IN VIVO POSITIONABLE FILTRATION DEVICES AND METHODS RELATED THERETOJuly 2022March 2024Allow2020YesNo
17856758IMPLANTABLE CRANIAL MEDICAL DEVICEJuly 2022March 2026Abandon4510NoNo
17834478Auto-Injector with CapJune 2022November 2025Allow4130YesNo
17778176DOSING SYRINGEMay 2022January 2026Allow4410YesNo
17734551METHOD FOR ELECTROPORATION CONTROLLED BY ELECTRICAL IMPEDENCE MEASUREMENTSMay 2022January 2024Allow2011YesNo
17773310FIXED DOSE INJECTION DEVICEApril 2022January 2026Allow4510YesNo
17703828AUTO SHUT OFF MALE LUER FITTINGMarch 2022December 2025Allow4511YesNo
17640862TRACK AND LOCKING MECHANISMS FOR INJECTION DEVICEMarch 2022February 2024Allow2410YesNo
17637936INJECTOR SYSTEM FOR DELIVERY OF A MEDICAL IMPLANTFebruary 2022December 2025Abandon4510NoNo
17679063Fenestrated infusion balloon catheter and methods of useFebruary 2022July 2025Allow4111YesNo
17637413NEEDLELESS SYRINGE HAVING MULTI-NOZZLE AND MANUFACTURING METHOD THEREFORFebruary 2022January 2026Allow4720NoNo
17673675INJECTION DEVICES AND SYSTEMS AND METHODS FOR USING THEMFebruary 2022February 2024Allow2411YesNo
17668572LAPAROSCOPIC ACCESS DEVICE WITH REAL-TIME MEASUREMENTSFebruary 2022September 2025Allow4311NoNo
17666138Implants for Localized Drug Delivery and Methods of Use ThereofFebruary 2022November 2023Allow2110YesNo
17629433TAMPER-EVIDENT CLOSUREJanuary 2022August 2025Allow4320NoNo
17575560Retrograde Blood Flow Occlusion Flushing DeviceJanuary 2022September 2025Abandon4451YesNo
17457722INTRAOCULAR GAS INJECTORDecember 2021June 2023Allow1910NoNo
17542218ACTIVATION SYSTEM AND METHOD FOR ON-BODY MEDICAL DEVICESDecember 2021May 2023Allow1710NoNo
17457006SYSTEM AND METHODS FOR INTRACRANIAL VESSEL ACCESSNovember 2021July 2023Allow2010YesNo
17526268MEDICAMENT DELIVERY DEVICENovember 2021January 2024Allow2611YesNo
17520397MALE LUER WITH FLUID PATH AND VENT PATH SEALSNovember 2021April 2025Allow4120NoNo
17449221OCCLUDABLE INTRODUCER NEEDLESeptember 2021March 2023Allow1810YesNo
17426035AUTO-INJECTOR WITH CAPAugust 2021November 2025Allow5230YesNo
17404954SYRINGE ADAPTER FOR MEDICATIONAugust 2021May 2022Allow920YesNo
17391685CANNULAS HAVING WALL STRENGTHENING FEATURES, AND RELATED SYSTEMS AND METHODSAugust 2021April 2025Allow4541YesNo
17340840CHAMBERED DISPENSING DEVICES AND METHODSJune 2021May 2024Abandon3610NoNo
17309290Syringe For Storing And Dispensing A MaterialMay 2021March 2025Allow4640NoNo
17241927MICROPROJECTION ARRAYS WITH ENHANCED SKIN PENETRATING PROPERTIES AND METHODS THEREOFApril 2021May 2024Allow3730YesNo
17286210Magnetic Delivery System and Hydrogel Fixative for Therapeutic CellsApril 2021December 2024Allow4411YesNo
17280399AUTO-INJECTORMarch 2021December 2024Allow4520YesNo
17278968AUTO-INJECTORMarch 2021March 2026Allow6031YesNo
17278894FIXING DEVICE FOR FIXING A CATHETER ASSEMBLY TO A PATIENTMarch 2021January 2025Allow4650NoNo
17270616FLUID INJECTOR SYSTEM WITH IMPROVED RATIO PERFORMANCEFebruary 2021June 2025Allow5111YesNo
17269847DELIVERY DEVICE FOR MEDICAL TUBULAR BODYFebruary 2021January 2026Abandon5921YesNo
17150086METHOD AND SYSTEM FOR NEUROHYDRODISSECTIONJanuary 2021July 2024Allow4210YesNo
17259976PLATE ELECTRODESJanuary 2021May 2025Abandon5211NoNo
17147041LOCKABLE ADAPTER ASSEMBLYJanuary 2021October 2024Allow4530NoNo
17128122Syringe for Direct Use with Medical Ampoules and VialsDecember 2020July 2023Abandon3110NoNo
17122881CATHETER HANDLEDecember 2020January 2025Allow4930YesNo
17252165PEN NEEDLEDecember 2020November 2024Allow4711NoNo
17110588Focusing CatheterDecember 2020December 2025Allow6031YesNo
17101135SURGICAL ACCESS DEVICE WITH FIXATION MECHANISMNovember 2020July 2024Allow4411NoNo
16951987DRUG DELIVERY DEVICE HAVING A NEEDLE GUARD MECHANISM WITH A TUNABLE THRESHOLD OF RESISTANCE TO NEEDLE GUARD MOVEMENTNovember 2020September 2023Allow3480YesNo
17099925Active Injection GuideNovember 2020July 2024Allow4431YesNo
17098933MEDICATION DELIVERY SYSTEM WITH MASKNovember 2020January 2024Allow3820YesNo
17088937Dosing Control Coupling for Enteral Fluid Transfer and Enteral Couplings and SyringesNovember 2020September 2025Allow5861YesNo
17079291CATHETER DEVICES WITH VALVES AND RELATED METHODSOctober 2020October 2025Abandon5921NoNo
17048615DEVICE FOR INJECTING A SUBSTANCE INTO AN INTERLAYER OF A BODY TISSUE OR ORGANOctober 2020August 2025Allow5860NoYes
17046530INJECTION NEEDLE AND INJECTION DEVICEOctober 2020November 2025Abandon6040YesNo
17066867APPLICATOR FOR APPLYING A MICRONEEDLE DEVICE TO SKINOctober 2020January 2025Allow5121NoNo
17063442SYSTEMS FOR INHIBITING HETEROTOPIC OSSIFICATIONOctober 2020August 2025Allow5931YesNo
17060769Methods and Compositions for Restoring Homeostatic Capacity of a SubjectOctober 2020August 2024Allow4651YesNo
17035927DRUG DELIVERY DEVICESeptember 2020April 2024Allow4240YesNo
17035851DRUG DELIVERY DEVICE AND METHODS OF DELIVERING A DRUGSeptember 2020December 2024Allow5041YesNo
17033359HIATAL HERNIA TREATMENTSeptember 2020January 2023Allow2711NoNo
17009874RELEASABLE SEAL FOR CATHETER SYSTEMSeptember 2020August 2022Allow2410NoNo
16977213OPTIMIZING INITIAL ORGAN PRESERVATIONSeptember 2020December 2024Allow5121YesNo
17004753SUBMUCOSAL BIORESORBABLE DRUG ELUTING PLATFORMAugust 2020April 2025Allow5631YesNo
17002078INTRAOCULAR IMPLANT DELIVERY APPARATUS AND METHODS OF USE THEREOFAugust 2020September 2023Abandon3720NoNo
16998176PENILE INJECTION GUIDE AND COMPRESSION DEVICEAugust 2020August 2023Allow3610YesNo
16994151CONNECTION MECHANISM FOR AN AUXILIARY MODULEAugust 2020June 2025Allow5841YesNo
16992009Automated sequential injection and blood drawAugust 2020May 2024Abandon4520NoNo
16965865Surface Texturization for Rolling Diaphragm SyringeJuly 2020February 2025Abandon5461YesNo
16942459CATHETER SHAFT AND CATHETER AND METHOD FOR THE PRODUCTION THEREOFJuly 2020April 2025Allow5640NoNo
16936763EXPANDABLE SHEATHJuly 2020October 2025Allow6030NoNo
16918273Flow Indicator for an Infusion PumpJuly 2020April 2023Allow3411YesNo
16908387RIGID AND FLEXIBLE LAPAROSCOPIC MULTIPLE COMPONENT MATERIAL DISPENSING DEVICES AND METHODSJune 2020June 2024Allow4821NoNo
16772229READY-TO-USE CRYORESISTANT INJECTION DEVICEJune 2020April 2023Abandon3410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LALONDE, ALEXANDRA ELIZABETH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
41.8%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
17
Allowed After Appeal Filing
3
(17.6%)
Not Allowed After Appeal Filing
14
(82.4%)
Filing Benefit Percentile
21.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LALONDE, ALEXANDRA ELIZABETH - Prosecution Strategy Guide

Executive Summary

Examiner LALONDE, ALEXANDRA ELIZABETH works in Art Unit 3783 and has examined 302 patent applications in our dataset. With an allowance rate of 70.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner LALONDE, ALEXANDRA ELIZABETH's allowance rate of 70.2% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by LALONDE, ALEXANDRA ELIZABETH receive 3.05 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LALONDE, ALEXANDRA ELIZABETH is 42 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +34.6% benefit to allowance rate for applications examined by LALONDE, ALEXANDRA ELIZABETH. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.2% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.6% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.5% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.